<?xml version='1.0' encoding='utf-8'?>
<document id="17404111"><sentence text="Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling."><entity charOffset="18-34" id="DDI-PubMed.17404111.s1.e0" text="arsenic trioxide" /></sentence><sentence text="Constitutive signal transducer and activator of transcription 3 (STAT3) activity, observed in approximately 50% of acute myelogenous leukemia cases and associated with adverse treatment outcome, is down-regulated by arsenic trioxide (ATO)"><entity charOffset="216-232" id="DDI-PubMed.17404111.s2.e0" text="arsenic trioxide" /><entity charOffset="234-237" id="DDI-PubMed.17404111.s2.e1" text="ATO" /><pair ddi="false" e1="DDI-PubMed.17404111.s2.e0" e2="DDI-PubMed.17404111.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17404111.s2.e0" e2="DDI-PubMed.17404111.s2.e1" /></sentence><sentence text=" Heat shock protein (HSP) 90 is a molecular chaperone involved in signal transduction pathways" /><sentence text=" We hypothesized that HSP90 inhibitors will potentiate ATO effect on constitutive STAT3 activity and cell killing"><entity charOffset="55-57" id="DDI-PubMed.17404111.s4.e0" text="ATO" /></sentence><sentence text=" One concern was that the effect of ATO and HSP90 inhibitors will result in up-regulation of HSP70, a protein known to inhibit apoptosis"><entity charOffset="36-38" id="DDI-PubMed.17404111.s5.e0" text="ATO" /></sentence><sentence text="" /><sentence text="We have used a semimechanistic pharmacodynamic model to characterize concentration-effect relationships of ATO and HSP90 inhibitors on constitutive STAT3 activity, HSP70 expression, and cell death in a cell line model"><entity charOffset="107-109" id="DDI-PubMed.17404111.s7.e0" text="ATO" /></sentence><sentence text="" /><sentence text="Pharmacodynamic interaction of ATO and three HSP90 inhibitors showed synergistic interactions in inhibiting constitutive STAT3 activity and inducing cell death, in spite of a concurrent synergistic up-regulation of HSP70"><entity charOffset="31-33" id="DDI-PubMed.17404111.s9.e0" text="ATO" /></sentence><sentence text="" /><sentence text="These preliminary results provide a basis for studying the combined role of ATO with HSP90 inhibitors in acute myelogenous leukemia with constitutive STAT3 activity"><entity charOffset="76-78" id="DDI-PubMed.17404111.s11.e0" text="ATO" /></sentence><sentence text="" /></document>